Breakthrough drug trial aims to slash agonizing sickle cell pain episodes

NCT ID NCT04935879

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This completed Phase 3 trial tested whether inclacumab, given as an IV infusion every 12 weeks, could reduce the frequency of painful vaso-occlusive crises in people with sickle cell disease. The study involved 241 participants aged 12 and older who had experienced 2-10 painful crises in the previous year. Researchers compared inclacumab against a placebo over 48 weeks to see if it safely lowered crisis rates and delayed time to first crisis.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji

Adana, 01130, Turkey (Türkiye)
Ahmadu Bello University Teaching Hospital

Zaria, Kaduna State, 1100011, Nigeria
AinShams University Hospital

Cairo, 11588, Egypt
American University of Beirut Medical Center

Hamra, Beyrouth, Lebanon
Aminu Kano Teaching Hospital

Kano, 700233, Nigeria
Arkansas Children's Hospital

Little Rock, Arkansas, 72202, United States
Barau Dikko Teaching Hospital/Kaduna State University

Kaduna, 800212, Nigeria
Baskent University Hospital

Adana, Yuregir, 01250, Turkey (Türkiye)
CEPEC-Centro de Pesquisa Clinica

São Paulo, 08270-120, Brazil
Casa de Saúde Santa Marcelina

São Paulo, 08270-070, Brazil
Clinica de la Costa Ltda.

Barranquilla, Atlántico, 080020, Colombia
DUMC Investigational Drug Services Pharmacy

Durham, North Carolina, 27710, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute IDS Pharmacy

Boston, Massachusetts, 02215, United States
Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital

Lagos, 100254, Nigeria
Duke University Medical Center

Durham, North Carolina, 27705, United States
Faculty of Medicine Cairo University

Cairo, 11562, Egypt
Fundação Faculdade Regional de Medicina de São José do Rio Preto

São José do Rio Preto, São Paulo, 15090-000, Brazil
Gertrude's Children Hospital

Nairobi, 00100, Kenya
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP

Ribeirão Preto, São Paulo, 14051-140, Brazil
Hospital Pharmacy Services- Investigational Drug Services

Chicago, Illinois, 60612, United States
Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A

São Paulo, 01232-010, Brazil
Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Hôpital Henri Mondor

Créteil, 94010, France
Institut Universitaire du Cancer de Toulouse-Oncopole

Toulouse, 31059, France
Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael

Salvador, Estado de Bahia, 41253-190, Brazil
Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO

Rio de Janeiro, 20211-030, Brazil
International Cancer Institute

Eldoret, 30100, Kenya
Jacobi Medical Center

The Bronx, New York, 10461, United States
KEMRI/CRDR, Siaya, KEMRI Clinical Research Annex

Kisumu, Siaya County, 40600, Kenya
Kenya Medical Research Institute- Center for Respiratory Disease Research

Nairobi, 00100, Kenya
McGovern Medical School/Health Science Center Houston

Houston, Texas, 77030, United States
Memorial Hermann - TMC Investigational Drugs, IDS Pharmacy

Houston, Texas, 77030, United States
Memorial Hermann Hospital, Texas Medical Center - Clinical Research Unit (CRU)

Houston, Texas, 77030, United States
Mersin Universitesi Tip Fakultesi Saglik Arastirma ve Uygulama Merkezi Hastanesi

Yenişehir, Mersin, 33343, Turkey (Türkiye)
Multihemo Serviços Médicos S/A

Recife, Pernambuco, 50070-460, Brazil
NIMR-Mbeya Medical Research Center

Mbeya, Tanzania
National Hospital Abuja

Abuja, Federal Capital Territory, 900211, Nigeria
Nini Hospital

Tripoli, North Lebanon, Lebanon
Prince Mohammed bin Nasser Hospital

Jizan, Southern, 82943, Saudi Arabia
Rush University Medical Center

Chicago, Illinois, 60612, United States
Rush University Medical Center Investigator Pharmacy

Chicago, Illinois, 60612, United States
Sociedad de Oncologia y hematologia del Cesar S.A.S.

Valledupar, Cesar Department, 200001, Colombia
Strathmore University Medical Center - Center for Research in Therapeutic Sciences(CREATES)

Nairobi, 00200, Kenya
Sultan َQaboos University Hospital

Muscat, 123, Oman
UC Irvine Health

Orange, California, 92868, United States
UCI Center for clinical research

Orange, California, 92868, United States
UT Physicians Comprehensive Sickle Cell Clinic

Houston, Texas, 77030, United States
Uconn Health/Uconn John Dempsey Hospital/Neag Comprehensive Cancer Center/New England Sickle Cell

Farmington, Connecticut, 06030, United States
University of Abuja Teaching Hospital

Gwagwalada, Federal Capital Territory, 902101, Nigeria
University of Calabar Teaching Hospital

Calabar, Cross River State, 540242, Nigeria
University of Illinois Clinical Research Center (CRC)

Chicago, Illinois, 60612, United States
University of Illinois Hospital and Health Sciences System(UI Health)

Chicago, Illinois, 60612, United States
University of Michigan Hospitals - Michigan Medicine

Ann Arbor, Michigan, 48109, United States
University of Nigeria Teaching Hospital

Enugu, 460000, Nigeria
University of South Alabama Children's and Women's Hospital

Mobile, Alabama, 36604, United States
University of South Alabama Mitchell Cancer Institute

Mobile, Alabama, 36604, United States
University of South Alabama Strada Patient Care Center

Mobile, Alabama, 36604, United States

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE VASO-OCCLUSIVE CRISIS VASO-OCCLUSIVE PAIN EPISODE IN SICKLE CELL DISEASE